George, Sydney http://orcid.org/0000-0001-6274-9357
Carrico, Justin
Hicks, Katherine A.
Loukov, Dessi
Ng, Cheryl
Regan, Jessica
Giannelos, Nikolaos
Funding for this research was provided by:
GlaxoSmithKline Biologicals
Article History
Accepted: 4 March 2024
First Online: 11 April 2024
Declarations
:
: GlaxoSmithKline Biologicals SA funded this study (GSK study identifier: VEO-000312) and all costs related to the development of the publications<b>.</b>
: Sydney George is employed by GSK. Dessi Loukov, Cheryl Ng, Jessica Regan and Nikolaos Giannelos are employed by and hold shares in GSK. Justin Carrico and Katherine A. Hicks are employed by RTI Health Solutions and received consulting fees from GSK to perform the work disclosed in this publication. All authors declare no other financial and non-financial relationships and activities.
: SG, JC, KAH, DL, CN and NG were involved in the design of the study. SG, JC, and KAH collected and generated the data. All authors analyzed and/or interpreted the data and participated in the development of this manuscript. SG led the publication development and study design. All authors gave their final approval and are accountable for all aspects of the work.
: CAPT, 17–18 October 2022, Toronto, ON, Canada.
: The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: Not applicable.
: Not applicable.
: The model used during the current study is available from the corresponding author on reasonable request.
: Not applicable. GSK study identifier: VEO-000312.
: Shingrix is a trademark owned by or licensed to GSK.